Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States)

Cancer Causes and Control

Volumn 14, Issue 8, 2003, Pages 721-726

  Li, Li ^a   Yu, Herbert ^b   Schumacher, Fredrick ^a   Casey, Graham ^c   Witte, John S ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Case control study; Insulin like growth factors; Prostate cancer

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER RISK; CELL GROWTH; CONTROLLED STUDY; DISEASE ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN BLOOD LEVEL; UNITED STATES;

AGED; CASE-CONTROL STUDIES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK FACTORS; UNITED STATES;

EID: 0344010575     PISSN: 09575243     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026383824791     Document Type: Article

References (31)

1. Jemal A, Thomas A, Murray T, Thun M (2002) Cancer statistics. CA Cancer J Clin 52: 23-47.
2. Gann PH, Chatterton RT, Lee C (2001) Peptide growth factors as biomarkers of prostate cancer risk. Epidemiol Rev 23: 67-71.
3. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins. Biological actions. Endocr Rev 16: 3-34.
4. Macauly VM (1992) Insulin-like growth factors and cancer. Br J Cancer 65: 311-320.
5. Prager D, Li HL, Asa S, Melmed S (1994) Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA 91: 2181-2185.
6. Parrizas M, LeRoith D (1997) Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of the bcl-xL gene product. Endocrinology 138: 1355-1358.
7. Iwamura M, Sluss PM, Casamento JB, Cockett AT (1993) Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22: 243-252.
8. Pollak M, Beamer W, Zhang JC (1999) Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17: 383-390.
9. Cohen P, Peehl DM, Lamson G, Rosenfeld RG (1991) Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73: 401-407.
10. Rajah R, Valetinis B, Cohen P (1997) Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53-and IGF-independent mechanism. J Biol Chem 272: 12181-12188.
11. Chan JM, Stampfer MJ, Giovannucci E, et al. (1998) Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566.
12. Stattin P, Bylund A, Rinaldi S, et al. (2000) Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst 92: 1910-1917.
13. Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB (2000) Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. J Clin Endocrinol Metab 85: 4258-4265.
14. Wolk A, Mantzoros CS, Anderson SO, et al. (1998) Insulin like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 90: 911-915.
15. Chokkalingam AP, Pollak M, Fillmore CM, et al. (2001) Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomark Prev 10: 421-427.
16. Mantzoros CS, Tzonou A, Signorello JB, Stampfer M, Trichopoulos D, Adami HO (1997) Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 76: 115-118.
17. Finne P, Auvinen A, Koistinen H, et al. (2000) Insulin-like growth factor 1 is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 85: 2744-2747.
18. Djavan B, Bursa B, Seitz C, et al. (1999) Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 54: 603-606.
19. Witte JS, Gauderman WJ, Thomas DC (1999) Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interaction: basic family designs. Am J Epidemiol 149: 693-705.
20. Lubin JH, Hartge P (1984) Excluding controls: misapplications in case-control studies. Am J Epidemiol 120: 791-793.
21. Willett WC (1998) Nutritional Epidemiology. 2nd edn. New York: Oxford University Press, pp. 74-100.
22. Ma J, Pollak MN, Giovannucci E, et al. (1999) Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 91: 620-625.
23. Hankinson S, Willett WC, Coldditz GA, et al. (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351: 1393-1396.
24. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91: 151-156.
25. Cohen P, Clemmons DR, Rosenfeld RG (2000) Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res 10: 297-305.
26. Kaaks R, Rinaldi S, Lukanova A, et al. (2001) Correspondence re: Giovannucci et al., A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomark Prev 9: 345-349, 2000; Cancer Epidemiol Biomark Prev 10: 1103-1104.
27. Kaaks R, Rinaldi S, Lukanova A, et al. (2001) Correspondence re: Giovannucci et al., A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomark Prev 9: 345-349, 2000; Cancer Epidemiol Biomark Prev 10: 1103-1104.
28. Shi R, Berkel HJ, Yu H (2001) Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 85: 991-996.
29. Chan JM, Stampfer MJ, Ma J, et al. (2002) Insulin-like growth factor-I (IGF) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 94: 1099-1106.
30. Shariat SF, Lamb DJ, Kattan MW, et al. (2002) Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 20: 833-841.
31. Yu H, Nicar MR, Shi R, et al. (2001) Levels of insulin-like growth factor I (IGF-I) and IGF binding protein 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence. Urology 57: 471-475.